Medicare GLP-1 Bridge program: $50 Wegovy, Zepbound

Medicare open enrollment runs October 15 – December 7, 2026, and the Medicare GLP-1 Bridge program is a drug story worth reviewing before you pick a plan. The CMS demonstration, live since July 1, 2026, lets qualifying Part D beneficiaries fill Wegovy, Zepbound (KwikPen), or Foundayo for a flat $50 a month through December 31, 2027. Managed Healthcare Executive laid it out for health plans in a September 3, 2026 FAQ with Avalere Health principal Kylie Stengel[1]; CMS publishes the beneficiary rules on Medicare.gov.[2][4] Here is who qualifies, what the program costs, and where coverage stops short.

What is the Medicare GLP-1 Bridge program?

Regular Medicare Part D does not cover GLP-1 drugs used only for weight loss. The Medicare GLP-1 Bridge program is the exception: a short-term CMS demonstration, running July 1, 2026 through December 31, 2027, that gives eligible Part D beneficiaries access to certain GLP-1 weight-management drugs at a flat $50 copay per month.[2][3] Originally set to end in December 2026, it was extended through 2027.[6]

The program runs outside the normal Part D coverage and payment flow: drug plans carry no risk for Bridge drugs, do not have to opt in, and CMS handles prior authorization, claims, and payment through a single central processor in 2026.[2][5] There is no “enroll in the Bridge” step.

Does Medicare cover Wegovy and Zepbound in 2026?

For eligible beneficiaries, yes — with limits on which versions are covered. These drugs are covered at $50 a month through December 31, 2027:[4]

• Foundayo (orforglipron) — tablet, the program’s oral option
• Wegovy (semaglutide) — injection or tablet
• Zepbound (tirzepatide) — KwikPen only

Not covered under the Bridge: the single-dose Zepbound pen, Zepbound vials, and the other marketed GLP-1s — Ozempic, Mounjaro, Rybelsus, and Trulicity.[4] If your Part D plan already covers a GLP-1 for any reason, you keep getting it through the plan; the Bridge is for weight-management access only.[4][5]

How much do GLP-1 drugs cost on Medicare in 2026?

Under the Bridge, $50 a month, flat regardless of income, from July 1, 2026 through December 31, 2027.[2][4] The $50 does not count toward your Part D deductible or yearly out-of-pocket limit, low-income subsidy (Extra Help) does not apply, and Bridge drugs are not eligible for the Medicare Prescription Payment Plan.[2][4][5]

That $50 sits far below the brands’ list prices — 2026 trackers put those around $1,300 a month[8], and KFF calls the manufacturers’ $245 monthly net price “a substantial discount off prevailing list prices.”[6] For costs outside Medicare — telehealth, self-pay, insurance — see our 2026 GLP-1 cost guide. For the newest Health Canada authorization of a generic semaglutide — Sandoz’s, in September 2026 — and what it does and does not change about price, see our Canadian generic semaglutide explainer.

Who qualifies for the Medicare GLP-1 Bridge program?

Not everyone qualifies — CMS said at launch that not all Medicare beneficiaries will qualify.[3] All four of these must be true:[4]

1. Have Medicare Part D — a standalone drug plan (PDP) or Medicare Advantage with drug coverage (MA-PD). You do not qualify if your only coverage is a private fee-for-service (PFFS), cost contract, or PACE plan.
2. Not be eligible for a GLP-1 through your Medicare drug plan. If your plan already pays for a GLP-1 — including weight-management coverage filled at any point in 2026 — the Bridge is not your route.[4][5]
3. Not have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease — conditions CMS treats as Part D-coverable, where your drug plan may already be the route.[4][5]
4. Be 18 or older and meet one BMI tier: 35 or higher; or 30 or higher with certain types of heart failure, hard-to-control high blood pressure, or chronic kidney disease (stage 3a or above); or 27 or higher with prediabetes or a prior heart attack, stroke, or blocked arteries in the legs or arms.[4]

The demonstration is aimed at people who need a GLP-1 for weight management with no other Part D access.[3] On an employer plan instead? See the employer GLP-1 coverage gap. The 2026 lung signal does not change any of this: a UK records association between semaglutide and fewer asthma attacks and COPD flare-ups, presented at the ERS Congress, is observational and not peer-reviewed, and the researchers say people should not start a GLP-1 for a lung condition outside prescribing guidance — see our coverage of the ERS 2026 semaglutide asthma/COPD data.

How do you get Wegovy or Zepbound for $50 on Medicare?

It is a prescription flow, not a sign-up form. Per Medicare.gov:[4]

1. Talk to your doctor about whether a GLP-1 is right for you and whether you qualify.
2. If a covered drug is right for you, the pharmacy receives your prescription.
3. The pharmacy may ask for your Medicare ID (from your card, or via the last four digits of your Social Security number).
4. After the pharmacy confirms eligibility, your doctor submits Medicare’s approval form — prior authorization via the CMS central processor.[2][5]
5. Medicare sends you a letter saying the medicine is covered.
6. Pick it up and pay $50 for a one-month supply. Refills on the same drug need no new approval, even if your dose changes.[4]

Questions: Medicare.gov/glp1bridge or 1-800-MEDICARE (1-800-633-4227; TTY 1-877-486-2048).[4]

What open enrollment (Oct 15 – Dec 7, 2026) has to do with the Bridge

Medicare open enrollment runs October 15 – December 7 every year; the 2026 window governs 2027 coverage, with changes generally taking effect January 1, 2027.[7] You do not elect the Bridge during open enrollment — there is no “Bridge plan” — but the window matters for two reasons:

• You must hold Part D — standalone or through a Medicare Advantage plan — to use the Bridge, so open enrollment is when you get or change drug coverage.[4]
• If your plan already covers a GLP-1 for a Part D-coverable condition — type 2 diabetes, moderate-to-severe sleep apnea, MASH with liver fibrosis, or a cardiovascular-risk use — you are not Bridge-eligible, and plan coverage may be the better route; open enrollment is the time to compare.[4][5]

Takeaway: review your 2027 drug plan during open enrollment, then ask your doctor whether the Medicare GLP-1 Bridge program fits you.

Frequently asked questions

Does Medicare cover GLP-1 weight loss drugs?

Regular Medicare Part D does not cover GLP-1 drugs used only for weight loss. The Medicare GLP-1 Bridge program is the exception for eligible beneficiaries: through December 31, 2027, qualifying Part D beneficiaries can get Wegovy, Zepbound (KwikPen), or Foundayo for $50 a month. People with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease are not Bridge-eligible; their Part D plan may already cover a GLP-1.[4]

What is the Medicare GLP-1 Bridge program?

A short-term CMS demonstration, running July 1, 2026 through December 31, 2027, that gives eligible Medicare Part D beneficiaries access to certain GLP-1 drugs for weight management at a flat $50-per-month copay, regardless of income. It operates outside the regular Part D coverage and payment flow, and it is not a plan you enroll in.[2][3]

Does Medicare cover Wegovy?

Yes, for eligible beneficiaries: Wegovy (semaglutide), injection or tablet, is covered at $50 a month through the Medicare GLP-1 Bridge through December 31, 2027 — if you have Part D, are 18 or older, meet the BMI requirements, and are not already eligible for a GLP-1 through your drug plan (for example, for cardiovascular risk reduction).[4][5]

Is Zepbound covered by Medicare in 2026?

Zepbound (tirzepatide) is covered at $50 a month through the Medicare GLP-1 Bridge for eligible Part D beneficiaries — but only the KwikPen version. The single-dose Zepbound pen and Zepbound vials are not covered under the program.[4]

Can I get a GLP-1 drug on Medicare?

Through the Medicare GLP-1 Bridge, yes, if you qualify: Part D coverage, no GLP-1 eligibility through your drug plan, none of the disqualifying conditions (type 2 diabetes, moderate-to-severe sleep apnea, fatty liver disease), and the age and BMI requirements met. You do not sign up for the Bridge — your doctor prescribes, the pharmacy confirms eligibility, and your doctor submits a Medicare approval form. Since you must hold Part D, open enrollment (October 15 – December 7, 2026) is the window to get or change coverage. Call 1-800-MEDICARE with questions.[4]

Who qualifies for the Medicare GLP-1 Bridge program?

You must meet all four requirements: have Part D (standalone or Medicare Advantage with drug coverage); not be eligible for a GLP-1 through your drug plan; not have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease; and be 18 or older with a BMI of 35 or higher — or 30 or higher with heart failure, hard-to-control high blood pressure, or stage 3a or higher chronic kidney disease — or 27 or higher with prediabetes or a history of heart attack, stroke, or blocked arteries.[4]

How much do GLP-1 drugs cost on Medicare?

Under the Medicare GLP-1 Bridge, $50 a month, flat regardless of income, from July 1, 2026 through December 31, 2027. The $50 does not count toward your Part D deductible or yearly out-of-pocket limit, and low-income subsidies do not apply to it. List prices for these drugs are north of $1,000 a month.[6][8]

Sources

[1] Managed Healthcare Executive, Kylie Stengel (Avalere Health): FAQ: What health plans need to know about Medicare’s GLP-1 Bridge program ahead of open enrollment (Sept 3, 2026)

[2] CMS: Medicare GLP-1 Bridge program (accessed Sept 3, 2026)

[3] CMS press release: CMS Launches Medicare GLP-1 Bridge, Expanding Access to GLP-1 Medications (July 1, 2026)

[4] Medicare.gov: Medicare GLP-1 Bridge: GLP-1 Drugs for $50 a Month (CMS Product No. 12234, June 2026)

[5] CMS memo: Medicare GLP-1 Bridge: Expectations and Frequently Asked Questions for Part D Sponsors (June 10, 2026)

[6] KFF: CMS Extends Medicare’s Short-Term Bridge Program for GLP-1 Obesity Drug Coverage (April 23, 2026)

[7] CMS: Medicare Open Enrollment partner resources

[8] The RX Index: GLP-1 Price and Access Tracker (July 1, 2026)

Nothing in this article is medical advice. PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.